FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954165784> ?p ?o ?g. }

• W2954165784 endingPage "1451" @default.
• W2954165784 startingPage "1435" @default.
• W2954165784 abstract "Background: We previously identified a panel of five microRNAs (miRNAs) associated with biochemical recurrence and metastasis following prostatectomy from prostate cancer patients using next-generation sequencing-based whole miRNome sequencing and quantitative polymerase chain reaction-based validation analysis. In this study, we examined the mechanism of action of miR-139-5p, one of the downregulated miRNAs identified in the panel. Methods: Using a cohort of 585 patients treated with radical prostatectomy, we examined the prognostic significance of miR-139 (dichotomized around the median) using the Kaplan-Meier method and Cox proportional hazard models. We validated these results using The Cancer Genome Atlas (TCGA) data. We created cell lines that overexpressed miR-139 to confirm its targets as well as examine pathways through which miR-139 may function using cell-based assays. Results: Low miR-139 expression was significantly associated with a variety of prognostic factors in prostate cancer, including Gleason score, pathologic stage, margin positivity, and lymph node status. MiR-139 expression was associated with prognosis: the cumulative incidence of biochemical recurrence and metastasis were significantly lower among patients with high miR-139 expression (P = .0004 and .038, respectively). Validation in the TCGA data set showed a significant association between dichotomized miR-139 expression and biochemical recurrence (odds ratio, 0.52; 95% confidence interval, 0.33-0.82). Overexpression of miR-139 in prostate cancer cells led to a significant reduction in cell proliferation and migration compared with control cells, with cells arrested in G2 of cell cycle. IGF1R and AXL were identified as potential targets of miR-139 based on multiple miRNA-binding sites in 3′-untranslated regions of both the genes and their association with prostate cancer growth pathways. Luciferase assays verified AXL and IGF1R as direct targets of miR-139. Furthermore, immunoblotting of prostate cancer cells demonstrated IGF1R and AXL protein expression were inhibited by miR-139 treatment, which was reversed by the addition of miR-139 antagomir. Examination of the molecular mechanism of growth inhibition by miR-139 revealed the downregulation of activated AKT and cyclin D1, with upregulation of the CDK inhibitor p21. Conclusions: miR-139 is associated with improved prognosis in patients with localized prostate cancer, which may be mediated through downregulation of IGF1R and/or AXL and associated signaling pathway components." @default.
• W2954165784 created "2019-07-12" @default.
• W2954165784 creator A5006397330 @default.
• W2954165784 creator A5022308392 @default.
• W2954165784 creator A5029051972 @default.
• W2954165784 creator A5046895084 @default.
• W2954165784 creator A5047781154 @default.
• W2954165784 creator A5061895332 @default.
• W2954165784 creator A5090167552 @default.
• W2954165784 date "2019-07-03" @default.
• W2954165784 modified "2023-10-16" @default.
• W2954165784 title "MicroRNA‐139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXL" @default.
• W2954165784 cites W1146750028 @default.
• W2954165784 cites W1498692154 @default.
• W2954165784 cites W1599073270 @default.
• W2954165784 cites W1822522338 @default.
• W2954165784 cites W1876403508 @default.
• W2954165784 cites W1882000757 @default.
• W2954165784 cites W1969346834 @default.
• W2954165784 cites W1969385456 @default.
• W2954165784 cites W1969774788 @default.
• W2954165784 cites W1984326475 @default.
• W2954165784 cites W1985993090 @default.
• W2954165784 cites W1989403098 @default.
• W2954165784 cites W1990134250 @default.
• W2954165784 cites W1999330214 @default.
• W2954165784 cites W2000828354 @default.
• W2954165784 cites W2003445065 @default.
• W2954165784 cites W2019428111 @default.
• W2954165784 cites W2022386424 @default.
• W2954165784 cites W2030750084 @default.
• W2954165784 cites W2035147500 @default.
• W2954165784 cites W2035258932 @default.
• W2954165784 cites W2035568149 @default.
• W2954165784 cites W2039071845 @default.
• W2954165784 cites W2040291225 @default.
• W2954165784 cites W2043471647 @default.
• W2954165784 cites W2044057392 @default.
• W2954165784 cites W2049247618 @default.
• W2954165784 cites W2058719858 @default.
• W2954165784 cites W2067337319 @default.
• W2954165784 cites W2075404131 @default.
• W2954165784 cites W2076419765 @default.
• W2954165784 cites W2078626573 @default.
• W2954165784 cites W2081259798 @default.
• W2954165784 cites W2092810158 @default.
• W2954165784 cites W2096330942 @default.
• W2954165784 cites W2098412103 @default.
• W2954165784 cites W2100191289 @default.
• W2954165784 cites W2106382644 @default.
• W2954165784 cites W2108958930 @default.
• W2954165784 cites W2111067040 @default.
• W2954165784 cites W2117590778 @default.
• W2954165784 cites W2119874496 @default.
• W2954165784 cites W2120456037 @default.
• W2954165784 cites W2124378783 @default.
• W2954165784 cites W2124777963 @default.
• W2954165784 cites W2130979840 @default.
• W2954165784 cites W2135174193 @default.
• W2954165784 cites W2136306650 @default.
• W2954165784 cites W2136362813 @default.
• W2954165784 cites W2137713702 @default.
• W2954165784 cites W2137734450 @default.
• W2954165784 cites W2140883829 @default.
• W2954165784 cites W2146736665 @default.
• W2954165784 cites W2147242002 @default.
• W2954165784 cites W2151860429 @default.
• W2954165784 cites W2152580674 @default.
• W2954165784 cites W2155480439 @default.
• W2954165784 cites W2156524562 @default.
• W2954165784 cites W2182217094 @default.
• W2954165784 cites W2301645580 @default.
• W2954165784 cites W2308405773 @default.
• W2954165784 cites W2324368371 @default.
• W2954165784 cites W2335679869 @default.
• W2954165784 cites W2339920561 @default.
• W2954165784 cites W2516597671 @default.
• W2954165784 cites W2560678530 @default.
• W2954165784 cites W2568917916 @default.
• W2954165784 cites W2605108935 @default.
• W2954165784 cites W2613323481 @default.
• W2954165784 cites W2727499364 @default.
• W2954165784 cites W2739105502 @default.
• W2954165784 cites W2762351536 @default.
• W2954165784 cites W2783583678 @default.
• W2954165784 cites W2791603173 @default.
• W2954165784 cites W2796558260 @default.
• W2954165784 cites W2797323866 @default.
• W2954165784 cites W2805090945 @default.
• W2954165784 cites W2811340263 @default.
• W2954165784 cites W2889059526 @default.
• W2954165784 cites W2893026770 @default.
• W2954165784 cites W2899950342 @default.
• W2954165784 cites W43749485 @default.
• W2954165784 cites W81266651 @default.
• W2954165784 doi "https://doi.org/10.1002/pros.23871" @default.
• W2954165784 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31269290" @default.
• W2954165784 hasPublicationYear "2019" @default.

• next